Med-IQ
HCV Treatment Practicalities: Screening Patients, Managing Prior Authorizations, and Monitoring Patients

HCV Treatment Practicalities: Screening Patients, Managing Prior Authorizations, and Monitoring Patients

Audiocast
Online Course | Specialties: Family Medicine, Internal Medicine, Primary Care
Released: 12/23/2021
|
Expires: 12/22/2022
|
Max Credits: 0.75
Jump to Education

Faculty
Dawn Fishbein, MD, MS
Scientific Director, Viral Hepatitis Research
MedStar Health Research Institute
Medical Director, Hub Liaison Team Core, GHUCCTS CTSA
Associate Chair of Research, Department of Medicine
Attending Physician, Infectious Diseases
MedStar Washington Hospital Center
Washington, DC

Elana Rosenthal, MD
Co-Director, DC PFAP Hepatitis Clinical Research Program
Assistant Professor, Institute of Human Virology
Division of Infectious Diseases, University of Maryland School of Medicine
Baltimore, MD

Activity Planners
Amy Burdette, PhD
Manager, Educational Strategy & Content
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Discuss appropriate HCV staging and treatment strategies
  • Incorporate comprehensive HCV care strategies, including pre-treatment assessment and post-cure monitoring
  • Identify strategies to assist patients in lowering HCV treatment costs and/or increasing likelihood of insurance coverage

Target Audience
This activity is intended for primary care providers.

Statement of Need
Despite ongoing screening campaigns to identify and treat individuals with hepatitis C virus (HCV) infection, a substantial percentage of those with HCV remain unaware of their infection. Additionally, the incidence of acute HCV infection, which often has subtle or no specific symptoms, tripled from 2010 to 2016 due to the opioid epidemic. Thus, many infected individuals may be unknowingly spreading HCV to others and may also not be receiving appropriate care, thereby remaining susceptible to substantial HCV-related morbidity and mortality. Because primary care clinicians have a critical role in identifying and screening appropriate patients for HCV infection, it is important to provide them with up-to-date education about HCV screening recommendations, evolving treatment approaches, and key monitoring strategies both during and after treatment.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
This CME activity consists of a 0.75-credit audiocast. To receive credit, read the introductory CME material, watch the audiocast, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: December 23, 2021
Expiration Date: December 22, 2022
Estimated Time to Complete This Activity: 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Dawn Fishbein, MD, MS
Consulting fees/advisory boards: Gilead Sciences, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): AbbVie Inc.
Other (investigator): Gilead Sciences, Inc.

Elana Rosenthal, MD
Other (investigator): Gilead Sciences, Inc., Merck & Co., Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Gilead Sciences, Inc.

Copyrighted

Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • Despite the potential for HCV elimination, rates of new infections continue to climb—particularly in medically underserved communities
  • To address gaps in HCV screening and treatment, primary care providers should play a greater role in identifying individuals with HCV infection and initiating treatment
  • Simplified treatment and monitoring guidelines exist to help guide primary care providers and other clinicians in making management decisions for their patients with HCV infection
  • Many patients with HCV infection experience financial barriers to affording HCV treatment; primary care providers can use various strategies to ensure cost is not a barrier
View reference list.

Click “Continue” to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.